Pharmaceutical Executive
July 01, 2011
Issue PDF
0
0
Pedal to the Mettle
July 01, 2011
Features
0
0
What India's latest census tells us about current and future pharma opportunities.
July 01, 2011
Columns
0
0
While Europe's EFPIA preaches about embracing change, much remains to be done to prove the adjustment in philosophy
July 01, 2011
Columns
0
0
EAB Member Al Topin delivers 10 questions that should drive your brand-building marketing program.
July 01, 2011
Columns
0
0
If you can learn to understand patient and physician behavior, you are well on your way to strengthening the position of your product
July 01, 2011
0
0
A country that bridges East and West, old and new-while boasting a growing economy in Europe-is being looked to for its pool of talented industry resources
July 01, 2011
Columns
0
0
Sponsors must handle interchangeability, exclusivity, cost and coverage hurdles to win biosimilars game
July 01, 2011
Features
0
0
Pfizer's crizotinib development program combined organization, art, and science-and a large dose of unforeseen risk
July 01, 2011
From the Editor
0
0
More bad ideas on how to manage the healthcare burden are circulating beyond the stakeholders that initiated them
July 01, 2011
Features
0
0
The objective is to make most cancers a curable, chronic condition. But with soaring costs, crowded therapeutic competition, and new diagnostic reimbursement challenges ahead, can industry deliver?
July 01, 2011
Columns
0
0
'Like' and 'Dislike' practices in the virtual Facebook pharmaceutical world.
July 01, 2011
Features
0
0
Taking Onyx Pharmaceuticals to new heights – CEO Tony Coles talks to PharmExec about the midsize company's transition from adolescence to adulthood.